A 41-year-old male patient was diagnosed with refractory Hodgkin's lymphoma after autologous HPC-A transplantation. After salvage chemotherapy, he was scheduled for allogeneic HPC-A transplantation with reduced intensity conditioning from his 36-year-old brother.
The donor, with a body weight of 64 kg and a height of 170 cm, had no remarkable previous medical history. Physical examination, chest X-ray, electrocardiogram, complete blood count and blood chemistry were normal. Serological tests for Hepatitis B and C, EBV, Herpes virus 1 and 2, HIV and Toxoplasma were all negative. Anti-hepatitis A and CMV IgG was positive, but IgM was negative. Thrombophilia screening (TS) was normal. TS comprised testing for factor V Leiden G1691A, prothrombin G20210A, the thermolabile variant (C677T) of the methylene tetrahydrofolate reductase gene, protein C, protein S, factor VIII and homocysteine plasmatic levels, antithrombin III activity and acquired activated protein C resistance.
The donor received lenograstim as the G-CSF mobilization agent. G-CSF was given subcutaneously at a total dose of 10 mg/kg in two doses 12 h for 5 days (until the morning of the fifth day). The first G-CSF administration was performed in the hospital, and was then continued at the donor's home, either self-administered or given by the subject's family physician. WBC count before and 1 month after G-CSF administration was 8 Â 10 9 and 9 Â 10 9 per L, respectively, and the maximum leukocyte count achieved after G-CSF administration was 100 Â 10 9 per L. HPC-A collection was started in the outpatient clinic on the morning of day 5 (WBC count of 90 Â 10 9 per L; platelet count 200 Â 10 9 per L), and apheresis was performed with continuous-flow apheresis equipment (Fresenius cell separator, COM.TEC systems, Fresenius Kabi AG, Bad Homburg, Germany) using citrate-dextrose as the anticoagulant. Blood was processed through the antecubital vein. At 1 h after the start of the apheresis procedure, the donor developed shortness of breath, rapid breathing, chest pain and cough. The procedure was halted and his immediate vital signs showed a blood pressure (BP) of 100/67 mm Hg, a pulse rate of 120 per min, respiration rates (RR) of 24 per min, O 2 saturation of 89% and a body temperature of 36.7 1C. On physical examination, the lungs appeared normal. A clinical diagnosis of pulmonary embolism (PE) was suspected. In all, 1000 mg of hydrocortisone i.v., low MW heparin and oxygen were administered. Blood tests were undertaken to exclude significant secondary causes of PE. These included a full blood count, clotting status (PT, aPTT, TT), and assessment of renal function, liver enzymes and electrolytes. The blood tests showed a D-dimer level of 4285 ng/ml. Chest X-ray was normal and electrocardiogram showed a sinus tachycardia of 120 beats per minute and right bundle branch block. No dysfunction of the right side of the heart was seen on echocardiography, and cardiac troponins and brain natriuretic peptide levels were not elevated. Chest multislice computerized tomographic scan with radiocontrast agent (CTPA-computerized tomographic pulmonary angiography) showed multiple filling defects of the sub-segmental branches of the left pulmonary artery due to acute PE (Figures 1 and 2) . The donor had no evidence of deep venous thrombosis (DVT) concomitantly with the diagnosis of PE. He responded well to the treatment and improved clinically within 2 h with a regular pulse of 90 per min, BP 123/67 mm Hg, RR 16per min and O 2 saturation of 99% on air. He was kept under observation as an inpatient for 2 days and then discharged home. He remained well and, despite having experienced severe side effects, proceeded to donate his stem cells.
This donor had been assessed in accordance with local policy and fully satisfied the medical and physical criteria required for HPC mobilization. All protocols were followed strictly. The most common sources of embolism are proximal leg DVT or pelvic vein thromboses. Any risk factor for DVT also increases the risk that the venous clot will dislodge and migrate to the lung circulation. Development of thrombosis is classically due to alterations in blood flow caused by immobilization (after surgery, injury or long-distance air travel, pregnancy, obesity and cancer), factors in the vessel wall and factors affecting the properties of the blood (procoagulant state: oestrogen-containing hormonal contraception, genetic thrombophilia, acquired thrombophilia and cancer). The donor had been assessed medically with a full history, examination and blood tests, and had been deemed fit. We believe that we could not have predicted this clinical complication.
Several studies have documented the effect of G-CSF on the coagulation system in HPC donors following drug administration. 8, 9 G-CSF induces activation of endothelial cells and the coagulation system, increasing thrombotic risk. Intracellular proteases may be released, which act on endothelial cells and platelets, and may modify the haemostatic balance towards a prothrombotic state. Until now, no thrombotic events have been reported in normal subjects during G-CSF administration, suggesting that the transient alteration in the hemostatic markers reported in the literature does not indicate a real thrombotic risk for healthy persons. This is the first documented case of pulmonary micro-embolism after administration of G-CSF. Diagnosis was based on the clinical findings in combination with laboratory tests (D-dimer test) and imaging (CTPA). G-CSF has been reported to induce neutrophil aggregation, and a recent report suggests that the transient neutropenia following G-CSF administration in the mouse and nonhuman primate is associated with an accumulation of neutrophils within pulmonary vasculature. 10 It is possible that in this case, neutrophil aggregation in the presence of a high WBC count on the morning of the apheresis procedure (90 Â 10 9 per L) could have been precipitated by apheresis. The WBC was particularly high in this case and there may be merit in checking the WBC count during G-CSF mobilization in normal donors to possibly prevent such a phenomenon from occurring. Given the life-threatening nature of the incident and the fact that G-CSF is used extensively, we felt it appropriate to report this case. 
